$TSHA
Taysha Gene Therapies, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021010433 Filed on March 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.240M $11.11M
YoY Change 8446.15%
% of Gross Profit
Research & Development $5.500M $31.89M
YoY Change 83.33% 3121.52%
% of Gross Profit
Depreciation & Amortization $32.00K $9.000K
YoY Change
% of Gross Profit
Operating Expenses $32.09M $43.00M
YoY Change 474.68% 3739.46%
Operating Profit -$32.09M -$43.00M
YoY Change 474.68%
Interest Expense $66.00K $28.00K
YoY Change 144.44%
% of Operating Profit
Other Income/Expense, Net $66.00K -$17.01M
YoY Change -56.86%
Pretax Income -$32.02M -$60.01M
YoY Change 5258.04%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$32.02M -$60.01M
YoY Change 489.65% 5258.13%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$865.6K -$1.738M
COMMON SHARES
Basic Shares Outstanding 37.76M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $228.7M $251.3M
YoY Change
Cash & Equivalents $228.7M $251.3M $0.00
Short-Term Investments
Other Short-Term Assets $839.0K $6.600M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $239.6M $257.9M $15.00K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $2.500M $300.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $700.0K
YoY Change
Total Long-Term Assets $3.200M $1.000M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $239.6M $257.9M $15.00K
Total Long-Term Assets $3.200M $1.000M $0.00
Total Assets $242.8M $258.9M $15.00K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.100M $2.000M
YoY Change
Accrued Expenses $14.90M $5.100M $150.0K
YoY Change 2450.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.00M $7.100M $150.0K
YoY Change 3450.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.000M $500.0K
YoY Change
Total Long-Term Liabilities $1.000M $500.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $19.00M $7.100M $150.0K
Total Long-Term Liabilities $1.000M $500.0K
Total Liabilities $20.00M $7.600M $150.0K
YoY Change 3700.0%
SHAREHOLDERS EQUITY
Retained Earnings -$1.115M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $222.9M $251.3M -$135.0K
YoY Change
Total Liabilities & Shareholders Equity $242.8M $258.9M $15.00K
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$32.02M -$60.01M
YoY Change 489.65% 5258.13%
Depreciation, Depletion And Amortization $32.00K $9.000K
YoY Change
Cash From Operating Activities -$22.04M -$30.73M
YoY Change 1196.94%
INVESTING ACTIVITIES
Capital Expenditures $534.0K $82.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$9.000M
YoY Change
Cash From Investing Activities -$534.0K -$9.082M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 291.1M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -22.04M -30.73M
Cash From Investing Activities -534.0K -9.082M
Cash From Financing Activities 0.000 291.1M
Net Change In Cash -22.57M 251.3M
YoY Change -238.22%
FREE CASH FLOW
Cash From Operating Activities -$22.04M -$30.73M
Capital Expenditures $534.0K $82.00K
Free Cash Flow -$22.57M -$30.81M
YoY Change 1228.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75235
CY2020 dei City Area Code
CityAreaCode
214
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37761435
CY2019Q4 us-gaap Assets
Assets
15000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
257879000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
287000
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
0
CY2020Q4 us-gaap Assets
Assets
258881000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1994000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
150000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
150000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251253000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6626000
CY2019Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
15000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15000
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2020 dei Local Phone Number
LocalPhoneNumber
612-0000
CY2020 dei Security12b Title
Security12bTitle
Common stock, par value $0.00001 per share
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5135000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7129000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
450000
CY2020Q4 us-gaap Liabilities
Liabilities
7579000
CY2019Q4 us-gaap Liabilities
Liabilities
150000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
312428000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
980000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61126000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1115000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
251302000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-135000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
258881000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10895000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37761435
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10894999
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37761435
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17665683
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9625679
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10894999
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31893000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
987000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11109000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
128000
CY2020 us-gaap Operating Expenses
OperatingExpenses
43002000
us-gaap Operating Expenses
OperatingExpenses
1115000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
15145000
CY2020 tsha Temporary Equity Stock Issuance Of Preferred Stock Tranche Liability
TemporaryEquityStockIssuanceOfPreferredStockTrancheLiability
1050000
CY2020 us-gaap Profit Loss
ProfitLoss
-60011000
us-gaap Profit Loss
ProfitLoss
-1115000
CY2020 us-gaap Depreciation
Depreciation
9000
us-gaap Depreciation
Depreciation
0
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
251253000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
251253000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-43002000
us-gaap Operating Income Loss
OperatingIncomeLoss
-1115000
CY2020 tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
-17030000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
49000
CY2020 us-gaap Interest Expense
InterestExpense
28000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17009000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-60011000
us-gaap Net Income Loss
NetIncomeLoss
-1115000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
0
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
142240000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
165854000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3354000
tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
0
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
9000000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
980000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3354000
us-gaap Share Based Compensation
ShareBasedCompensation
0
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6585000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1961000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0
CY2020 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
4513000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
135000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30729000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0
CY2020 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
9000000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9082000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
165854000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1673000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2020 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1673000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
291064000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
28000
us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
214000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
0
CY2020 tsha Reclassification Of Preferred Stock Liability Upon Issuance Costs
ReclassificationOfPreferredStockLiabilityUponIssuanceCosts
18080000
tsha Reclassification Of Preferred Stock Liability Upon Issuance Costs
ReclassificationOfPreferredStockLiabilityUponIssuanceCosts
0
CY2020 tsha Allocation Of Preferred Stock Tranche Liability
AllocationOfPreferredStockTrancheLiability
1050000
tsha Allocation Of Preferred Stock Tranche Liability
AllocationOfPreferredStockTrancheLiability
0
CY2020 tsha Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
142240000
tsha Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9782000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
234000
CY2020Q2 tsha Mile Stone Shares Issued
MileStoneSharesIssued
200000
CY2018 tsha Net Operating Loss Carryforward Percentage
NetOperatingLossCarryforwardPercentage
0.80
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0006
CY2020 tsha Effective Income Tax Rate Reconciliation General Business Credits
EffectiveIncomeTaxRateReconciliationGeneralBusinessCredits
0.0106
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company&#8217;s financial statements relate to the determination of the fair value of the common stock prior to the IPO (as an input into stock-based compensation), estimating preclinical manufacturing accruals and accrued or prepaid research and development expenses, and the valuation of the preferred stock tranche liability. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.</p>
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9782000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
234000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
7.52
CY2020Q3 tsha Common Stock Fair Value Per Share
CommonStockFairValuePerShare
5.28
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3354000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits.</p>
CY2020 tsha Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0025
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1591
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2100
CY2020 tsha Effective Income Tax Rate Reconciliation Change In Fair Value Of Tranche Liability
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfTrancheLiability
-0.0596
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5810000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9500000
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
200000
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0
CY2020Q4 us-gaap Property Subject To Or Available For Operating Lease Number Of Units
PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits
187500
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60011000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1115000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4293953
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 tsha Net Operating Loss Carryforward Percentage
NetOperatingLossCarryforwardPercentage
0.80
CY2019 tsha Net Operating Loss Carryforward Percentage
NetOperatingLossCarryforwardPercentage
0.80
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
672000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
334000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
21000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2390000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
206000
CY2019Q4 tsha Deferred Tax Assets Organizational And Start Up Costs
DeferredTaxAssetsOrganizationalAndStartUpCosts
28000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
555000
CY2020Q4 us-gaap Operations Commenced Date1
OperationsCommencedDate1
2021-04-01
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P15Y6M
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020 tsha Operating Leases Initial Direct Costs
OperatingLeasesInitialDirectCosts
800000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
314000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1282000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1317000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1354000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1391000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
17599000
CY2020Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
944000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
740000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
32685000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15647052
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 tsha Preferred Stock Tranche Liability
PreferredStockTrancheLiability
1100000
CY2020Q2 tsha Change In Fair Value Of Preferred Stock Tranche Liability
ChangeInFairValueOfPreferredStockTrancheLiability
17000000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23257000
CY2020Q3 tsha Mile Stone Shares Issued
MileStoneSharesIssued
4000000
CY2020Q3 tsha Amount Reclassified To Convertible Preferred Stock
AmountReclassifiedToConvertiblePreferredStock
18100000
CY2020 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
296000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9000
CY2020Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2106000
CY2019Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
7000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1766000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
999000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
122000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
264000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2480000
CY2020Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
2462000

Files In Submission

Name View Source Status
0001564590-21-010433-index-headers.html Edgar Link pending
0001564590-21-010433-index.html Edgar Link pending
0001564590-21-010433.txt Edgar Link pending
0001564590-21-010433-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gq1uonsnyiul000001.jpg Edgar Link pending
gq1uonsnyiul000002.jpg Edgar Link pending
gq1uonsnyiul000003.jpg Edgar Link pending
gq1uonsnyiul000004.jpg Edgar Link pending
gq1uonsnyiul000005.jpg Edgar Link pending
gq1uonsnyiul000006.jpg Edgar Link pending
gq1uonsnyiul000007.jpg Edgar Link pending
gq1uonsnyiul000008.jpg Edgar Link pending
gq1uonsnyiul000009.jpg Edgar Link pending
gq1uonsnyiul000010.jpg Edgar Link pending
gq1uonsnyiul000011.jpg Edgar Link pending
gq1uonsnyiul000012.jpg Edgar Link pending
gq1uonsnyiul000013.jpg Edgar Link pending
gq1uonsnyiul000014.jpg Edgar Link pending
gq1uonsnyiul000015.jpg Edgar Link pending
gq1uonsnyiul000016.jpg Edgar Link pending
gq1uonsnyiul000017.jpg Edgar Link pending
gq1uonsnyiul000018.jpg Edgar Link pending
gq1uonsnyiul000019.jpg Edgar Link pending
gq1uonsnyiul000020.jpg Edgar Link pending
gq1uonsnyiul000021.jpg Edgar Link pending
gq1uonsnyiul000022.jpg Edgar Link pending
gq1uonsnyiul000023.jpg Edgar Link pending
gq1uonsnyiul000024.jpg Edgar Link pending
gq1uonsnyiul000025.jpg Edgar Link pending
gq1uonsnyiul000026.jpg Edgar Link pending
gq1uonsnyiul000027.jpg Edgar Link pending
gq1uonsnyiul000028.jpg Edgar Link pending
gq1uonsnyiul000029.jpg Edgar Link pending
gq1uonsnyiul000030.jpg Edgar Link pending
gq1uonsnyiul000031.jpg Edgar Link pending
gq1uonsnyiul000032.jpg Edgar Link pending
gq1uonsnyiul000033.jpg Edgar Link pending
gq1uonsnyiul000034.jpg Edgar Link pending
gq1uonsnyiul000035.jpg Edgar Link pending
gq1uonsnyiul000036.jpg Edgar Link pending
gq1uonsnyiul000037.jpg Edgar Link pending
gq1uonsnyiul000038.jpg Edgar Link pending
gq1uonsnyiul000039.jpg Edgar Link pending
gq1uonsnyiul000040.jpg Edgar Link pending
gq1uonsnyiul000041.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-10k_20201231.htm Edgar Link pending
tsha-20201231.xml Edgar Link completed
tsha-20201231.xsd Edgar Link pending
tsha-20201231_cal.xml Edgar Link unprocessable
tsha-20201231_def.xml Edgar Link unprocessable
tsha-20201231_lab.xml Edgar Link unprocessable
tsha-20201231_pre.xml Edgar Link unprocessable
tsha-ex1013_851.htm Edgar Link pending
tsha-ex1014_852.htm Edgar Link pending
tsha-ex1015_1051.htm Edgar Link pending
tsha-ex105_792.htm Edgar Link pending
tsha-ex231_1464.htm Edgar Link pending
tsha-ex311_9.htm Edgar Link pending
tsha-ex312_8.htm Edgar Link pending
tsha-ex321_6.htm Edgar Link pending
tsha-ex322_7.htm Edgar Link pending
tsha-ex42_791.htm Edgar Link pending